Blog Layout

COVID19 Vaccines Explained

WHICH VACCINE WILL AUSTRALIA USE?

February 2021


Australia’s COVID vaccine rollout scheduled to begin in mid- to late February. Vaccination will commence with workers dealing with international arrivals or quarantine facilities, frontline health workers and those living in aged care or with a disability. Read more: https://theconversation.com/australias-vaccine-rollout-will-now-start-next-month-heres-what-well-need-152612


The Australian Government announced on the 6th Jan 2021, that the first rollout of vaccines will be Pfizer-BioNtech of which the Government has secured 10 million doses. Followed by 50 million doses of Oxford AstraZeneca vaccine produced in Victoria. Each of these vaccines will be subject to approval by the TGA (Therapeutic Goods Association).


WHY ARE WE NOT RUSHING TO START VACCINATING IN AUSTRALIA

The vaccines in the UK and the USA have only received ‘emergency approval’ of the vaccines currently being distributed which means stage 3 trials are not finished but the demand is too great to wait as both countries are in dire situations with increasing COVID-19 cases and though we have active cases currently, our situation is much better controlled. The TGA would rather wait to receive the full trial results before giving approval. This is expected to now in February 2021.


In January 2021, there were more than 200 vaccine candidates around the world, 48 of which are in clinical trials. To see the latest on the vaccine landscape click here: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.


To ensure Australians will have access to COVID-19 vaccines, the federal government established agreements with suppliers of four of the most promising vaccine candidates. The vaccines have been carefully assessed on advice from a Science and Industry Technical Advisory Group.


So far, the vaccines for which Australia are considering include the AstraZeneca/University of Oxford vaccine, the Novavax vaccine, and the Pfizer/BioNTech vaccine. There is also possibly the Novavax vaccine which is still in phase 3 trials which is manufactured in the USA.


One big question surrounding all of the coronavirus vaccines, is whether they prevent asymptomatic infections as well as illness caused by the virus. Reducing asymptomatic infections, when people can spread the virus without knowing they have it, could have a big impact on slowing the spread of the disease. The Oxford data found some evidence of reduced asymptomatic infections in those who received the half-dose followed by a full dose later.


No one knows for how long coronavirus vaccine provides protection. Some vaccines are effective for years, but for obvious reasons this will take longer to confirm.

 


Read more: What do we know about the Novavax and Pfizer COVID vaccines

 

The Pfizer/BioNTech vaccine, which is currently being administered in the UK, is chemically made - using genetic material. These vaccines are created using new technology, known as mRNA, which introduces a genetic code the body can use to make its own viral protein to induce an immune response. 



These agreements will only progress in Australia should the vaccines prove safe and effective, as assessed by the TGA, which will look at the quality of the vaccine, the degree of protection it offers, and its safety. At this stage, the TGA have not approved either vaccine to be administered in Australia.


Read More: Information from WHO re vaccine development

Read more: The AstraZeneca Oxford University Vaccine


 

REACTION - REPORT OF SEVERE ALLERGIES REPORTED FROM THE UK

10th December 2020: Britain's medical regulator has warned that people with a history of serious allergic reactions should not get the COVID-19 vaccine from Pfizer and BioNTech


Key points:

  • People with a history of severe allergic reactions to vaccine, medicine or food are now being told to not take the vaccine
  • This advice is not uncommon as several vaccines already on the market carry warnings about allergic reactions and subsequent precautionary measures such as the use of ‘epipen’ or having the vaccination is facilities which have resuscitation equipment
  • Late-stage vaccine trials in the UK found "no serious safety concerns"
  • The medical director of the NHS in England says both affected patients are recovering

 

WHY KEEP PFIZER/BIONTECH SUPERCOLD?

The most important challenge for development of a mRNA vaccine remains its inherent instability, because it is more likely to break apart above freezing temperatures.


The vaccine needs to be stored at -80 degrees until the last few days, then stored in a vaccine suitable fridge. Dosage is recommended as 2 doses 21 days apart


VACCINATIONS FOR CHILDREN under 12 – UPDATE

The vaccine is being tested in adults 18-54 years of age, 55-85 years of age and adolescents 12-18 years of age. The Pfizer/BioNTech vaccine is the first COVID-19 vaccine to be tested in adolescents.


There is no COVID-19 vaccine being developed specifically for children. So if children are to be vaccinated, they will likely receive the same vaccine as adults.


Children might require a different dosing schedule, but that is not yet clear. The way a child’s immune system reacts to pathogens or vaccines can be different to adults. Age can determine the number of required doses. For example, infants sometimes require more doses of a vaccine than older children. Age can also influence the side-effect profile of a vaccine. For example, mild fever following vaccination can be common in babies and young children.


Vaccine trials are usually done in stages. They typically start with healthy, young and middle-aged adults.


Once a vaccine is confirmed to be safe in these earlier trials, developers then test the vaccine in older and younger age groups.


There are no protocols yet including children in COVID-19 vaccine trials run in Australia. Any Australian studies would only likely examine the immune response and safety in children (phase 1 and 2 trials). They would probably not examine effectiveness (phase 3 trials) because of the low rates of COVID-19 here.

  • Researchers will need to examine the dosages, interval between doses, and the number of doses which work best in children.
  • This process could take several months
  • Kids may not have an approved vaccine until middle or late 2021.

 

UPDATE RE COVID-19 VACCINE DISTRIBUTION

The ATAGI has provided preliminary advice regarding COVID-19 vaccines strategy for procurement and program delivery for 2021. This document discusses efficacy, duration or protection, targeted groups and modes of delivery. As a summary, those identified as high risk are a priority.

 

UPDATE AS TO WHO IS PRIORITY TO RECEIVE THESE VACCINES?

The Australian COVID-19 Vaccination Policy, endorsed by the National Cabinet on 13 November 2020 discusses the Federal Government selecting and purchasing the vaccines, decide who gets the vaccines and set the standards for the immunisation program.


State and Territory governments will deliver the immunisation program from specified locations. On page 12 it says: Workplace vaccinations: Some larger corporations and high-risk workplaces may establish workplace vaccination clinics in partnership with State and Territory health services or private providers.

While we are still to see what NSW Health decides and what is the most effective and efficient way for our workforce to receive vaccinations, there is no formal approval from Australia to begin a roll out, as approval must first be sought from the TGA (Therapeutic Goods Administration).  It will be interesting to see how the UK responds. Herd immunity isn’t really a consideration for entire population as the BioNTech-Pfizer COVID-19 Vaccine is possible not suitable for children under 12 at this stage. Possible more doses for at risk groups such as those who are immunocompromised. For further information regarding this vaccine, see link from the Australian Government. 

16 Jan, 2024
Since 2019, the business landscape has undergone significant transformations in the wake of the global COVID-19 pandemic. As we step into 2024, companies worldwide continue to grapple with the evolving challenges and opportunities presented by the ongoing pandemic. In 2023, COVID-19 produced a new strain called JN.1: Question is do we need to panic? The short answer is NO. The World Health Organisation (WHO) has labelled JN.1 as a “variant of interest" (VOI), a designation given to certain variants of a virus, such as the SARS-CoV-2 virus that causes COVID-19. VOI’s are closely monitored due to specific characteristics that may have implications for public health efforts. The criteria for designating a variant as a VOI may vary by health organizations. Generally, a variant of interest may exhibit one or more of the following features: Increased Transmission: The variant may show evidence of increased transmissibility, meaning it spreads more easily from person to person. Impact on Diagnostics, Treatments, or Vaccines: There may be concerns that the variant could impact the effectiveness of diagnostic tests, treatments, or vaccines. Potential for Increased Severity: The variant might be associated with more severe disease outcomes. Increased Resistance to Immunity: There could be indications that the variant is less susceptible to immunity generated through previous infection or vaccination. It's important to note that the designation of a variant as a "variant of interest" does not necessarily mean that it poses a significant threat . It is a classification used by health authorities to draw attention to certain variants that warrant closer monitoring and further investigation. If a variant demonstrates increased risk and becomes more concerning, it may be reclassified as a "variant of concern." Public health agencies, such as the WHO and national health organizations, regularly assess and classify variants based on these criteria to inform public health measures and strategies. Monitoring and understanding the characteristics of variants are crucial components of the ongoing efforts to control and manage the spread of infectious diseases. The U.S. Centres for Disease Control and Prevention (CDC) at the time provided an update on the JN.1 subvariant. According to the CDC, there is currently no evidence suggesting that JN.1 poses an elevated risk to public health compared to other variants currently in circulation. Moreover, the CDC reassured that individuals who receive an updated vaccine shot can continue to be effectively protected against this specific variant. So what do we need to do? Continue to implement robust health protocols, including regular sanitization, social distancing measures, and if appropriate vaccination policies. Also monitor public health messaging and adjust accordingly, ensuring that you prioritise the safety of employees and customers not only protects public health but also builds trust in the brand. As businesses chart their course in 2024, the lessons learned from the COVID-19 pandemic should continue to shape your strategies and priorities. Fostering resilience, prioritising employee well-being, and maintaining a customer-centric focus are key pillars for success in the post-COVID era. By staying agile and innovative, businesses can not only weather uncertainties but also thrive in a rapidly evolving business landscape.
By glen 12 Jul, 2023
There is a reason why events have Safety Supervisors on site, and not Risk Supervisors. In any situation, ensuring a safe and secure work environment is of paramount importance. To achieve this, companies often have dedicated professionals responsible for managing risks and promoting safety. These professionals are known as risk supervisors and safety supervisors. In this blog, we will explore the key differences between these two roles and help you determine which one your event may need. What is a Safety Supervisor? A safety supervisor, also referred to as a safety officer or safety coordinator, is responsible for promoting and maintaining a safe working environment for employees. Their primary objective is to prevent accidents, injuries, and occupational hazards by implementing safety protocols, conducting inspections, and providing safety training to employees. Safety supervisors monitor compliance with safety regulations, investigate incidents, and develop strategies to minimize workplace risks. They possess strong communication and organizational skills. What is a Risk Supervisor? A risk supervisor, also known as a risk manager or risk assessor, plays a crucial role in identifying, assessing, and mitigating potential risks that can impact an organization's operations, assets, or reputation. Their primary focus is on analyzing the probability and potential impact of risks, developing risk management strategies, and implementing risk control measures. Risk supervisors work closely with various stakeholders to ensure risks are identified and addressed effectively. They typically possess strong analytical and problem-solving skills. How do you get both without breaking the budget? At SaveLife, during pre-production or event planning stage we focus on Risk Management, primarily focusing on identifying and managing risks that can impact the organization, including financial, legal, and reputational risks. Analysing risks at a broader level, considering the overall impact on the client’s objectives and strategies. It is during the pre-production stage our risk supervisors apply their strong analytical, problem-solving, and strategic thinking abilities. Applying risk assessment methodologies and knowledge of various risk management frameworks. Once the event or production is underway, our experts become Safety Supervisors, concentrating on ensuring the physical safety and well-being of employees within the workplace. Safety supervisors, focus on specific workplace safety measures and compliance with regulations. Calling on their excellent communication, training, and inspection skills, along with a deep understanding of occupational health and safety regulations. Conclusion In conclusion, both risk supervisors and safety supervisors play vital roles in maintaining a safe and secure work environment. It is key that the person you engage has the skills and experience to understand the differences between these roles and how to move between each function smoothly. Doing so will ensure the well-being of your employees and the overall success of your event or production.
By glen 12 Jul, 2023
Introduction: In today's fast-paced and competitive world, productions and event organisers are increasingly recognizing the importance of prioritizing employee morale. A positive work environment not only enhances productivity but also fosters loyalty and job satisfaction amongst the team. One of the key factors that contribute to a high morale is safety. In this blog post, we will explore how safety boosts morale and discuss the various ways in which organizations can create a safe work environment for their employees. 1. Safety as a Confidence Booster: When your team feel safe and secure in their workplace, it instils a sense of confidence in them. Knowing that their employer prioritizes their well-being and takes necessary precautions to ensure their safety, employees are more likely to feel valued and motivated. This confidence translates into higher job satisfaction and a positive attitude towards work, ultimately boosting morale. 2. Reduced Stress and Anxiety: A safe work environment significantly reduces stress and anxiety amongst the team. When employees are confident that they are protected from potential hazards and risks, they can focus better on their tasks and responsibilities. This reduction in stress levels allows the team to feel more relaxed, leading to an increase in job satisfaction and overall morale. 3. Increased Productivity: Safety measures and protocols in the workplace not only protect everyone from accidents but also create an atmosphere conducive to productivity. When the team are not constantly worried about their well-being, they can concentrate on their work more effectively. This increased focus and productivity have a direct impact on employee morale, as they feel a sense of accomplishment and fulfillment. 4. Trust and Loyalty: A safe work environment fosters trust and loyalty. When the team feel that management genuinely cares about their safety, they are more likely to develop a sense of loyalty towards the company. This loyalty strengthens the bond between the team and production, leading to higher job satisfaction and increased morale. 5. Positive Company Culture: Safety initiatives and practices contribute to shaping a positive company culture. By prioritizing safety, organizations send a clear message to the team that their well-being matters. This commitment to safety creates a sense of unity and fosters a positive work environment, where employees feel valued and supported. A positive company culture, in turn, enhances morale and helps in attracting and retaining top talent. Conclusion: A safe work environment is a crucial factor in boosting team morale. By prioritizing safety, organizations not only protect everyone from potential hazards but also create a positive work atmosphere that fosters loyalty, trust, and productivity. Investing in safety measures and promoting a culture of safety can significantly enhance employee morale, leading to a happier and more productive workforce.
Share by: